GIM
JAZZ icon

Glenmede Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Glenmede Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.03M Sell
7,826
-22,431
-74% -$2.69M 0.01% 698
2025
Q2 		$3.21M Buy
+30,257
New +$3.29M 0.02% 503

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Glenmede Investment Management's JAZZ Position: Q3 2025 in Review

Glenmede Investment Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 74% in Q3 2025, selling an estimated $2.69M and leaving 7,826 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #698.

Glenmede Investment Management first reported a position in JAZZ in Q2 2025 and has held it in 2 quarters since. The position peaked at $3.21M in Q2 2025. 502 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • Glenmede Investment Management held 7,826 shares of Jazz Pharmaceuticals worth $1.03M as of Q3 2025.
  • Glenmede Investment Management sold 22,431 Jazz Pharmaceuticals shares in Q3 2025, an estimated $2.69M.
  • Jazz Pharmaceuticals made up 0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #698 holding.
  • Glenmede Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Jazz Pharmaceuticals position peaked at $3.21M in Q2 2025.
  • 502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.